• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Wellington Partners (Group)

Wellington Partners is a leading European Venture Capital firm investing in early- and growth stage life science companies. Wellington Partners is focused on investing in the most promising life science companies in the fields of biotechnology, therapeutics, medical technology, diagnostics and digital health. With funds totalling EUR 1.0 billion, and more than EUR 400 million committed to Life Sciences, Wellington Partners has been actively supporting world class private companies translating true innovation into successful businesses with exceptional growth. To date, Wellington Partners has invested in 46 innovative life science companies, including Actelion (acquired by J&J), Definiens (acquired by AZ/Medimmune), Invendo (acquired by Ambu), MTM laboratories (acquired by Roche), Rigontec (acquired by MSD), Symetis (acquired by Boston Scientific), Immatics and AMBOSS. *

 

	Start	1998-01-01 established
	Today	Wellington Partners Venture Capital GmbH
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Strohmenger, Rainer (Wellington Partners Venture Capital 201303 General Partner)
	Person 2	Essig, Stuart M. (Wellington Partners 201303– Venture Partner before Integra Life Sciences CEO + Goldman Sachs)
	Region	München (Munich)
	Country	Germany
	Street	5 Türkenstr.
	City	80333 München
	Tel	+49-89-219941-0
		Address record changed: 2019-07-31
Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	1,000,000,000 (capital under management (2018) 2018-11-26)
		* Document for �About Section�: Wellington Partners. (7/31/19). "Press Release: Wellington Partners Raises EUR 210 Million Life Science Fund".
		Record changed: 2019-11-09

Advertisement

More documents for Wellington Partners (Group)

• [1] Wellington Partners. (7/31/19). "Press Release: Wellington Partners Raises EUR 210 Million Life Science Fund"....
• [2] Confo Therapeutics N.V.. (5/7/19). "Press Release: Confo Therapeutics Raises €30 Million in Series A Financing". Ghent....
• [3] Snipr Biome ApS. (3/11/19). "Press Release: Snipr Biome Raises $50 Million Series A Financing to Advance CRISPR-based Microbiome Drugs to Human Clinical Trials". Copenhagen....
• [4] CMS Hasche Sigle. (12/3/18). "Press Release: CMS berät Wellington und HBM als Lead Investoren der Serie D-Finanzierungsrunde der Adrenomed". München....
• [5] Themis Bioscience GmbH. (11/28/16). "Press Release: Themis Bioscience Successfully Closes 10 M EUR Financing Round". Vienna....
• [6] UroMems. (11/15/16). "Press Release: UroMems Closes €14m Financing to Develop Its Smart Artificial Urinary Sphincter to Market". Grenoble....
• [7] Neuway Pharma GmbH. (10/22/15). "Press Release: Neuway Pharma Extends First Round Financing to € 5.85 Million". Bonn....
• [8] Themis Bioscience GmbH. (5/5/15). "Press Release: Themis Bioscience Raises up to EUR 10 Million in Series B. New Board to Drive Partnerships and Commercialization of Product Pipeline". Vienna....
• [9] Imevax GmbH. (10/28/14). "Press Release: Imevax Secures EUR 7.5 Million in Series A Financing to Develop Highly Specific Vaccine against Helicobacter pylori Infections". Munich....
• [10] Neuway Pharma GmbH. (7/16/14). "Press Release: Neuway Pharma GmbH Appoints Dr. Stephan Rapp as CEO". Bonn....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.